Patents
Literature
18 results about "Acid sphingomyelinase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Acid sphingomyelinase is one of the enzymes that make up the sphingomyelinase (SMase) family, responsible for catalyzing the breakdown of sphingomyelin to ceramide and phosphorylcholine. They are organized into alkaline, neutral, and acidic SMase depending on the pH in which their enzymatic activity is optimal. Acid Sphingomyelinases (aSMases) enzymatic activity can be influenced by lipids, cations, pH, redox and other proteins in the environment. Specifically aSMases have been shown to have increased enzymatic activity in lysobisphophatidic acid (LBPA) or phosphatidylinositol (PI) enriched environments, and inhibited activity when phosphorylated derivatives of PI are present.
Ultra low dosage zoledronic acid for treatment of retinal disease
Provided herein are method of treating retinal disease using a bisphosphonate acid sphingomyelinase (ASM) and farnesyl diphosphate synthase (FDPS) inhibitor, such as zoledronic acid, at low doses.
Owner:RGT UNIV OF CALIFORNIA +1
Dose-escalating enzyme replacement therapy for the treatment of acid sphingomyelinase deficiency
Owner:MAUNT SINAJ SKUL OF MEDSIN +1
Pharmaceutical recombinant human acid sphingomyelinase compositions and methods
Disclosed herein are compositions comprising recombinant acid sphingomyelinase (rASM) having a desired purity, specific activity and / or rASM isoform. Methods for producing and purifying such compositions, including chromatography steps, are also provided. Additionally, methods for modulating rASM specific activity in a composition, and methods for modulating rASM isoform in a composition are provided. The methods disclosed herein may be particularly useful for the preparation of pharmaceutical compositions comprising rASM for treating acid sphingomyelinase deficiency (ASMD).
Owner:GENZYME CORP
Treatment Strategies for Pancreatic Cancer Using Recombinant Acid Sphingomyelinase
A method of treating pancreatic adenocarcinoma in an individual is disclosed. The method involves administering to the individual a therapeutically effective amount of a therapeutic agent comprising recombinant acid sphingomyelinase. In one embodiment, the therapeutic agent further includes one or more compositions selected from the group consisting of modified enzymes, fusion proteins and constitutively active mutants. In another embodiment, the therapeutic agent further includes a pharmaceutically acceptable excipient.
Owner:UNIVERSITY OF CINCINNATI
Recombinant human acidic sphingomyelinase pharmaceutical compositions and methods
PendingCN119365593AMetabolism disorderPeptide/protein ingredientsPharmacy medicinePharmaceutical drug
Disclosed herein are compositions comprising recombinant acidic sphingomyelinase (rASM) having desired purity, specific activity, and / or rASM subtypes. Also provided are methods for making and purifying such compositions, the methods comprising a chromatography step. Further provided are methods of modulating the specific activity of rASM in compositions, as well as methods of modulating rASM subtypes in compositions. The methods disclosed herein are particularly useful for the manufacture of pharmaceutical compositions comprising rASM for the treatment of acid sphingomyelinase deficiency (ASMD).
Owner:GENZYME CORP
Hydroxamic acid derivative and application thereof
The invention relates to a hydroxamic acid derivative and application thereof, in particular to a compound shown in the formula I and a pharmaceutically acceptable salt or prodrug thereof, and the compound shown in the formula I has good inhibitory activity on acid sphingomyelinase and has better pharmacokinetic property compared with a parent drug. # imgabs0 #
Owner:CHINA PHARM UNIV
Method for treating a degenerative neurological disorders comprising administering ASM inhibitor
The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor as an active ingredient.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
Antibody specifically binding to ASM and use thereof
The present invention relates to an antibody that specifically binding to acid sphingomyelinase (ASM) and a use thereof and, more specifically to an anti-ASM monoclonal antibody which has very high binding sensitivity and specificity to ASM protein and an excellent inhibitory effect on ASM activity, and to a use thereof in treatment / diagnosis of neurodegenerative diseases.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
Ultralow dose zoledronic acid for treatment of retinal diseases
Provided herein are methods of treating retinal diseases using low doses of bisphosphonate hydrosphingomyelinase (ASM) and a farnesyl diphosphate synthase (FDPS) inhibitor, such as zoledronic acid.
Owner:RGT UNIV OF CALIFORNIA +1
Application of amitriptyline in acidic sphingomyelinase deficiency, Gaucher disease, spherical cell white matter dystrophy and Niemann-Pick type C
The invention provides application of amitriptyline in treatment of acid sphingomyelinase deficiency, Gaucher disease, spherical cell white matter dystrophy and Niemann-Pick type C.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells
ActiveUS12550885B2Dead animal preservationBlood/immune system cellsRed blood cellAcid sphingomyelinase
Methods, additive kits and storage compositions for decreasing the deleterious effects of storage on pRBCs, for improving the aging process of stored pRBCs, and for preventing or ameliorating patient comorbidities following the transfusion or infusion of stored blood based on inhibiting acid sphingomyelinase during storage are provided.
Owner:UNIVERSITY OF CINCINNATI
Culture medium for pluripotent stem cells
The present invention relates to a chemically defined medium for eukaryotic cell culture, comprising water, at least one carbon source, one or more vitamins, one or more salts, one or more fatty acids, one or more buffer components, selenium, at least one substance of the group of Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and at least one polypeptide of the TGF-β superfamily with the ability to inhibit stem cell differentiation, its use in the culture of human pluripotent stem cells, a cell culture system comprising human pluripotent stem cells and the chemically defined medium, as well as a kit for proliferation and / or maintenance of human pluripotent stem cells.
Owner:PROMOCELL GMBH
Antibody specifically binding to acidic sphingomyelinase protein
The present invention relates to an antibody capable of specifically binding to an acid sphingomyelinase (ASM) protein, and a use thereof, and more particularly, to an antibody capable of specifically binding to an acid sphingomyelinase (ASM) protein. Specifically, the antibody or the antigen-binding fragment thereof according to the present invention binds to acidic sphingomyelin protein with a specifically high binding force, and thus can be used for detecting acidic sphingomyelin protein or diagnosing diseases caused by overexpression of acidic sphingomyelin protein.
Owner:ISU ABXIS
Use of amitriptyline in acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann-Pick type C
The present application provides the application of amitriptyline in the treatment of acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann Pick type C.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Marker for acid sphingomyelinase disorders and uses thereof
The present disclosure provides methods of screening, diagnosing, monitoring and / or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and / or treatment of an ASM disorder, for example using enzyme replacement therapy.
Owner:GENZYME CORP
Antibody specifically binding to ASM protein
The present invention relates to an antibody specifically binding to an acid sphingomyelinase (ASM) protein. Particularly, the antibody or an antigen-binding fragment thereof, according to the present invention, specifically binds to the ASM protein, with high binding affinity, and, thus, can be effectively used for detecting the ASM protein or diagnosing, etc. a disease occurring due to overexpression of the ASM protein.
Owner:ISU ABXIS
Pharmaceutical compositions for treating acid sphingomyelinase deficiency
This invention provides a composition for treating acid sphingomyelinase deficiency (ASMD). [Solution] A composition comprising recombinant human acid sphingomyelinase, sodium phosphate, methionine, and sucrose is provided. A method for using the composition to treat patients with acid sphingomyelinase deficiency is also provided.
Owner:GENZYME CORP
ANTIBODIES THAT BIND SPECIFICALLY TO AN ASM PROTEIN
The present invention relates to an antibody specifically binding to an acid sphingomyelinase (ASM) protein. Particularly, the antibody or an antigen-binding fragment thereof, according to the present invention, specifically binds to the ASM protein, with high binding affinity, and, thus, can be effectively used for detecting the ASM protein or diagnosing, etc. a disease occurring due to overexpression of the ASM protein.
Owner:ISU ABXIS